{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:18:19Z","timestamp":1787980699463,"version":"build-2784847793"},"reference-count":304,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Arizona College of Pharmacy faculty startup fund"},{"id":[{"id":"https:\/\/ror.org\/03m2x1q45","id-type":"ROR","asserted-by":"publisher"}]},{"name":"R. Ken and Donna Coit Endowed Chair fund in Drug Discovery"},{"name":"NIH","award":["AI177149"],"award-info":[{"award-number":["AI177149"]}]},{"name":"NIH","award":["AI175435"],"award-info":[{"award-number":["AI175435"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Human respiratory viruses represent a major global health burden, causing millions of severe infections and deaths annually. Despite the central role of vaccines in prevention, their limitations, such as incomplete coverage, waning immunity, and vulnerability to viral evolution, underscore the urgent need for effective antiviral therapeutics. This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets. Key viral proteins, including RNA-dependent RNA polymerases, proteases, and fusion glycoproteins, are analyzed across major virus families such as coronaviruses, paramyxoviruses, and adenoviruses, highlighting their structural features, functional constraints, and therapeutic potential. We further explore the integration of high-throughput screening and rational drug design, supported by advances in structural biology, cryo-electron microscopy, and computational approaches, including artificial intelligence-driven drug discovery. These methodologies collectively enhance the precision and efficiency of antiviral development. However, significant challenges remain, particularly the conflict between viral mutation and target conservation, the rapid emergence of drug resistance, and the safety limitations of host-targeted therapies. Finally, we discuss emerging strategies to overcome these barriers, including combination therapies and the development of broad-spectrum antivirals targeting conserved molecular mechanisms. This paper highlights a framework for the rational design of durable antiviral interventions capable of addressing both existing and emerging respiratory viral threats.<\/jats:p>","DOI":"10.3390\/pathogens15090903","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:47:13Z","timestamp":1787849233000},"page":"903","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target-Based Antiviral Drug Development Against Human Respiratory Viruses"],"prefix":"10.3390","volume":"15","author":[{"given":"Subodh Kumar","family":"Samrat","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-1798","authenticated-orcid":false,"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 E Mabel St, Tucson, AZ 85721, USA"},{"name":"Department of Chemistry & Biochemistry, College of Science & College of Medicine, The University of Arizona, Tucson, AZ 85721, USA"},{"name":"The BIO5 Institute, The University of Arizona, Tucson, AZ 85721, USA"},{"name":"Department of Molecular & Cellular Biology, College of Science, The University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, M., Liu, M., and Liu, J. (2025). Trends in the Mortality, Deaths, and Aetiologies of Lower Respiratory Infections Among 204 Countries from 1991 to 2021: An Updated Systematic Study. Viruses, 17.","DOI":"10.3390\/v17070892"},{"key":"ref_2","unstructured":"(2026, August 12). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/respiratory-syncytial-virus-(rsv)."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (2026, August 12). CDC Yellow Book: Health Information for International Travel, Available online: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/influenza.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a038695","DOI":"10.1101\/cshperspect.a038695","article-title":"The 1918 Influenza Pandemic and Its Legacy","volume":"10","author":"Taubenberger","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","unstructured":"World Health Organization (2024). WHO Data."},{"key":"ref_6","unstructured":"Falsey, A.R., and Branche, A.R. (2017). International Encyclopedia of Public Health, Elsevier."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4168\/aair.2025.17.4.414","article-title":"Clinical Significance of Rhinoviruses and Progress Toward Vaccination","volume":"17","author":"Lee","year":"2025","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40121-024-01082-2","article-title":"Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations","volume":"14","author":"Maggi","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Livieratos, A., Schiro, L.E., Gogos, C., and Akinosoglou, K. (2024). Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2. Vaccines, 12.","DOI":"10.3390\/vaccines12121444"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QCO.0000000000001184","article-title":"Antiviral therapies for respiratory syncytial virus infection: Current expectations","volume":"39","author":"Taveras","year":"2026","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_13","unstructured":"(2026, August 12). Available online: https:\/\/www.cdc.gov\/rhinoviruses\/about\/index.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase inhibitors: Zanamivir and oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E420","DOI":"10.1503\/cmaj.100313","article-title":"Oseltamivir-resistant pandemic H1N1 influenza","volume":"183","author":"Webster","year":"2011","journal-title":"Can. Med. Assoc. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3904\/kjim.2023.357","article-title":"The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: A systematic review stratified by disease severity","volume":"39","author":"Ryoo","year":"2024","journal-title":"Korean J. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bansal, V., Mahapure, K.S., Bhurwal, A., Gupta, I., Hassanain, S., Makadia, J., Madas, N., Armaly, P., Singh, R., and Mehra, I. (2020). Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. Front. Med., 7.","DOI":"10.3389\/fmed.2020.606429"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/jmv.27730","article-title":"Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review","volume":"94","author":"Masyeni","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/0113892002320326250123082112","article-title":"Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data","volume":"25","author":"Maideen","year":"2024","journal-title":"Curr. Drug Metab."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Perelson, A.S., Ribeiro, R.M., and Phan, T. (2023). An explanation for SARS-CoV-2 rebound after Paxlovid treatment. medRxiv.","DOI":"10.1101\/2023.05.30.23290747"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/378304","article-title":"Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada","volume":"37","author":"Knowles","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pleschka, S. (2024). Special Issue \u201cHost Targeted Therapeutics Against Virus Infections\u201d. Viruses, 16.","DOI":"10.3390\/v16121825"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Alanazi, A., Ibrahim, M.N., El Azab, E.F., and Elithy, M.A. (2026). Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets. Viruses, 18.","DOI":"10.3390\/v18010125"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104074","DOI":"10.1016\/j.drudis.2024.104074","article-title":"Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities","volume":"29","author":"Dai","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101972","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_29","unstructured":"Centers for Disease Control and Prevention (2025). CDC Yellow Book: Health Information for International Travel."},{"key":"ref_30","unstructured":"Centers for Disease Control and Prevention (2026). Influenza (Flu)."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fukao, K., Ando, Y., Noshi, T., Kitano, M., Noda, T., Kawai, M., Yoshida, R., Sato, A., Shishido, T., and Naito, A. (2019). Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217307"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dufrasne, F. (2021). Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010028"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.apsb.2025.02.015","article-title":"Advances in development of antiviral strategies against respiratory syncytial virus","volume":"15","author":"Yang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12910","DOI":"10.1074\/jbc.REV120.013930","article-title":"The molecular virology of coronaviruses","volume":"295","author":"Hartenian","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2020.10.091","article-title":"The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2","volume":"538","author":"Jin","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105360","DOI":"10.1016\/j.antiviral.2022.105360","article-title":"Conserved coronavirus proteins as targets of broad-spectrum antivirals","volume":"204","author":"Bobrowski","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014Drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37546","DOI":"10.1038\/s41598-025-15979-6","article-title":"SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation","volume":"15","author":"Ataya","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Cort\u00e9s, G.I., Palacios-P\u00e9rez, M., Veled\u00edaz, H.F., Hern\u00e1ndez-Aguilar, M., L\u00f3pez-Hern\u00e1ndez, G.R., Zamudio, G.S., and Jos\u00e9, M.V. (2022). The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. Vaccines, 10.","DOI":"10.3390\/vaccines10060864"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/1389450122666210906154849","article-title":"Exploring the SARS-CoV-2 Main Protease (M(pro)) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19","volume":"23","author":"Tarannum","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"Feldmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lyles, K.V., Stone, S., Singh, P., Patterson, L.D., Natekar, J., Pathak, H., Varshnaya, R.K., Elsharkawy, A., Liu, D., and Bansal, S. (2025). Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein. Viruses, 17.","DOI":"10.3390\/v17070989"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-020-00927-w","article-title":"RNA-binding proteins in tumor progression","volume":"13","author":"Qin","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Venkataraman, S., Prasad, B., and Selvarajan, R. (2018). RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. Viruses, 10.","DOI":"10.3390\/v10020076"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Riley, T.P., Chou, H.T., Hu, R., Bzymek, K.P., Correia, A.R., Partin, A.C., Li, D., Gong, D., Wang, Z., and Yu, X. (2021). Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.660198"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zan, F., Zhou, Y., Chen, T., Chen, Y., Mu, Z., Qian, Z., and Ou, X. (2024). Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit. Viruses, 16.","DOI":"10.3390\/v16020223"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Huynh, T., Cornell, W., and Luan, B. (2020). In silico Exploration of Inhibitors for SARS-CoV-2\u2019s Papain-Like Protease. Front. Chem., 8.","DOI":"10.3389\/fchem.2020.624163"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"120284","DOI":"10.1016\/j.lfs.2021.120284","article-title":"ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors","volume":"293","author":"Portales","year":"2022","journal-title":"Life Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/B978-0-12-809633-8.21501-X","article-title":"Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae)","volume":"2","author":"Liu","year":"2021","journal-title":"Encycl. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0422023","DOI":"10.1128\/spectrum.04220-23","article-title":"Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics","volume":"12","author":"Siragam","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2119467119","DOI":"10.1073\/pnas.2119467119","article-title":"Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle","volume":"119","author":"Yang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.7150\/thno.48076","article-title":"SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy","volume":"10","author":"Datta","year":"2020","journal-title":"Theranostics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"104833","DOI":"10.1016\/j.phrs.2020.104833","article-title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor","volume":"157","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11675","DOI":"10.1038\/s41467-025-66693-w","article-title":"Effect of the S2\u2019 site cleavage on SARS-CoV-2 spike","volume":"16","author":"Shi","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ghimire, D., Han, Y., and Lu, M. (2022). Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Viruses, 14.","DOI":"10.3390\/v14061255"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jinf.2021.06.001","article-title":"Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks","volume":"83","author":"Fantini","year":"2021","journal-title":"J. Infect."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Soares, V.C., Moreira, I.B.G., and Dias, S.S.G. (2025). SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. Viruses, 17.","DOI":"10.3390\/v17081064"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"106449","DOI":"10.1016\/j.compbiomed.2022.106449","article-title":"SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations","volume":"153","author":"Tumskiy","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2519755122","DOI":"10.1073\/pnas.2519755122","article-title":"Molecular basis of SARS-CoV-2 proofreading enzyme-mediated resistance to remdesivir","volume":"122","author":"Yang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103004","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gammeltoft, K.A., Zhou, Y., Ryberg, L.A., Pham, L.V., Binderup, A., Hernandez, C.R.D., Offersgaard, A., Fahn\u00f8e, U., Peters, G.H.J., and Ramirez, S. (2023). Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Viruses, 15.","DOI":"10.3390\/v15091970"},{"key":"ref_69","first-page":"20499361251321724","article-title":"Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: A narrative literature review","volume":"12","author":"Mukae","year":"2025","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14656566.2024.2323597","article-title":"Simnotrelvir as a potential treatment for COVID-19","volume":"25","author":"McCarthy","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: A multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/qub2.60","article-title":"Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS-CoV-2 variants and other coronaviruses","volume":"12","author":"Zhao","year":"2024","journal-title":"Quant. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wu, X., Devine, S.M., Go, M., Nguyen, J.V., Lu, B.G.C., Loi, K., Kuchel, N.W., Lowes, K.N., Mitchell, J.P., and Lessene, G. (2025). Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. PLoS Pathog., 21.","DOI":"10.1371\/journal.ppat.1013468"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eadd0082","DOI":"10.1126\/scisignal.add0082","article-title":"The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING","volume":"16","author":"Cao","year":"2023","journal-title":"Sci. Signal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543784.2022.2030310","article-title":"Monoclonal antibody therapies in the management of SARS-CoV-2 infection","volume":"31","author":"Choi","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: Development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.14423\/SMJ.0000000000001503","article-title":"Banning Monoclonal Antibody Therapies for COVID-19 Using In Vitro Data","volume":"116","author":"Zitek","year":"2023","journal-title":"South. Med. J."},{"key":"ref_81","unstructured":"(2026, August 12). Available online: https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/coronavirus-covid-19-drugs."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"110698","DOI":"10.1016\/j.biopha.2020.110698","article-title":"The role of Interleukin 6 inhibitors in therapy of severe COVID-19","volume":"131","author":"Nasonov","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MS9.0000000000004621","article-title":"Immunomodulatory strategies for managing cytokine storms in chronic COVID: Mechanisms, therapeutic targets, and clinical advances","volume":"88","author":"Obeagu","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/cts.13569","article-title":"Anticoagulant therapy in COVID-19: A narrative review","volume":"16","author":"Hosseinzadeh","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106101","DOI":"10.1016\/j.antiviral.2025.106101","article-title":"Host-targeted antivirals against SARS-CoV-2 in clinical development\u2014Prospect or disappointment?","volume":"235","author":"Schreiber","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"116069","DOI":"10.1016\/j.ejmech.2023.116069","article-title":"Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s44259-025-00125-z","article-title":"Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals","volume":"3","author":"Aw","year":"2025","journal-title":"NPJ Antimicrob. Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fvl-2021-0335","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a target for high-throughput drug screening","volume":"18","author":"Wu","year":"2022","journal-title":"Future Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e0086922","DOI":"10.1128\/mbio.00869-22","article-title":"Genetic Surveillance of SARS-CoV-2 M(pro) Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid","volume":"13","author":"Lee","year":"2022","journal-title":"mBio"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Fang, P., Fang, L., Zhang, H., Xia, S., and Xiao, S. (2021). Functions of Coronavirus Accessory Proteins: Overview of the State of the Art. Viruses, 13.","DOI":"10.3390\/v13061139"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Piasecka, J., Jarmolowicz, A., and Kierzek, E. (2020). Organization of the Influenza A Virus Genomic RNA in the Viral Replication Cycle-Structure, Interactions, and Implications for the Emergence of New Strains. Pathogens, 9.","DOI":"10.3390\/pathogens9110951"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med. Res. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.jmb.2017.06.015","article-title":"A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus","volume":"429","author":"Wu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"a038778","DOI":"10.1101\/cshperspect.a038778","article-title":"Influenza Hemagglutinin Structures and Antibody Recognition","volume":"10","author":"Wu","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2174\/0929867325666180706112940","article-title":"Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development","volume":"26","author":"Zhang","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"104765","DOI":"10.1016\/j.jbc.2023.104765","article-title":"Structural dynamics reveal subtype-specific activation and inhibition of influenza virus hemagglutinin","volume":"299","author":"Garcia","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2009-1-2-26-32","article-title":"Influenza virus neuraminidase: Structure and function","volume":"1","author":"Shtyrya","year":"2009","journal-title":"Acta Naturae"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41586-019-1530-7","article-title":"Structures of influenza A virus RNA polymerase offer insight into viral genome replication","volume":"573","author":"Fan","year":"2019","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9450","DOI":"10.1021\/acs.jpcb.3c05257","article-title":"Molecular Mechanisms behind Conformational Transitions of the Influenza Virus Hemagglutinin Membrane Anchor","volume":"127","author":"Michalski","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41467-022-29416-z","article-title":"Structure-based design of stabilized recombinant influenza neuraminidase tetramers","volume":"13","author":"Ellis","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4614-0980-9_9","article-title":"Influenza virus entry","volume":"726","author":"Luo","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Byrd-Leotis, L., Cummings, R.D., and Steinhauer, D.A. (2017). The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071541"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.jbc.2021.100486","article-title":"The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor","volume":"296","author":"Todd","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/infdis\/jiz418","article-title":"Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains","volume":"221","author":"Checkmahomed","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/jix606","article-title":"Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus","volume":"217","author":"Kiso","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Alame, M.M., Massaad, E., and Zaraket, H. (2016). Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.00450"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: An intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2429627","DOI":"10.1080\/22221751.2024.2429627","article-title":"Influenza neuraminidase mutations and resistance to neuraminidase inhibitors","volume":"13","author":"Xu","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Scott, C., Kankanala, J., Foster, T.L., Goldhill, D.H., Bao, P., Simmons, K., Pingen, M., Bentham, M., Atkins, E., and Loundras, E. (2020). Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008716"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Mahrous, N.N., Alhumaidan, O.S., Alkhoshaiban, A.S., Tafish, R.T., Al-Ghnnam, F.F., Althubyani, M., Al-Hubaysh, A., and Jamous, Y.F. (2025). Broadly neutralizing monoclonal antibodies against influenza A viruses: Current insights and future directions. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1738181"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101492","DOI":"10.1016\/j.coviro.2025.101492","article-title":"Host-targeted antivirals as broad-spectrum inhibitors of respiratory viruses","volume":"73","author":"Beran","year":"2025","journal-title":"Curr. Opin. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Hui, X., Ding, S., Gao, S., Xu, S., Zhao, T., Tian, X., and Wang, H. (2026). Host-Directed Antiviral Strategies Against Influenza Viruses: Host Targets, Multi-Omics Approaches and AI-Assisted Discovery. Vet. Sci., 13.","DOI":"10.3390\/vetsci13070626"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"101311","DOI":"10.1016\/j.nexres.2026.101311","article-title":"Emerging host-targeted antivirals for respiratory viruses: Antivirals targeting virus elements versus host mechanisms","volume":"5","author":"Matsunaga","year":"2026","journal-title":"Next Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1128\/JVI.00724-07","article-title":"Peptide-mediated interference with influenza A virus polymerase","volume":"81","author":"Ghanem","year":"2007","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Laborda, P., Wang, S.Y., and Voglmeir, J. (2016). Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. Molecules, 21.","DOI":"10.3390\/molecules21111513"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.micinf.2005.12.008","article-title":"Roles of neuraminidase in the initial stage of influenza virus infection","volume":"8","author":"Ohuchi","year":"2006","journal-title":"Microbes Infect."},{"key":"ref_121","first-page":"S149","article-title":"Novel hemagglutinin-based influenza virus inhibitors","volume":"5","author":"Shen","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"116172","DOI":"10.1016\/j.ejmech.2024.116172","article-title":"Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations","volume":"267","author":"Kumar","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"104780","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: Plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"a038380","DOI":"10.1101\/cshperspect.a038380","article-title":"Accessory Gene Products of Influenza A Virus","volume":"11","author":"Pinto","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_125","unstructured":"Chamarthi, S., Chamarthi, V.S., and Daley, S.F. (2026). Respiratory Syncytial Virus Infection in Children. StatPearls, StatPearls Publishing."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bergeron, H.C., and Tripp, R.A. (2022). RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. Viruses, 14.","DOI":"10.3390\/v14112396"},{"key":"ref_127","first-page":"e36342","article-title":"Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation","volume":"15","author":"Kaler","year":"2023","journal-title":"Cureus"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/JVI.76.11.5654-5666.2002","article-title":"Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"ref_129","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1099\/vir.0.049254-0","article-title":"RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function","volume":"94","author":"Tian","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1099\/vir.0.80010-0","article-title":"A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): Modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and function of the BRSV fusion protein","volume":"85","author":"Giesow","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Asseri, A.A. (2025). Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113880"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Cao, D., Gao, Y., and Liang, B. (2021). Structural Insights into the Respiratory Syncytial Virus RNA Synthesis Complexes. Viruses, 13.","DOI":"10.3390\/v13050834"},{"key":"ref_134","first-page":"3","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1099\/vir.0.053025-0","article-title":"The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid","volume":"94","author":"Bakker","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e0163924","DOI":"10.1128\/jvi.01639-24","article-title":"Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain","volume":"98","author":"Neal","year":"2024","journal-title":"J. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/idr16050081","article-title":"The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China","volume":"16","author":"Wang","year":"2024","journal-title":"Infect. Dis. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"105318","DOI":"10.1016\/j.ebiom.2024.105318","article-title":"The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis","volume":"107","author":"Anderson","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yu, D., Zhang, C., Qi, Y., Liu, Z., Yang, D., Zhao, N., Ke, Z., Lu, X., and Li, Y. (2025). RSV Vaccines: Targeting Prefusion F and G Proteins from Structural Design to Clinical Application. Vaccines, 13.","DOI":"10.3390\/vaccines13111133"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"131756","DOI":"10.1016\/j.molstruc.2021.131756","article-title":"RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases","volume":"1250","author":"Pathania","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1039\/D0MD00318B","article-title":"Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses","volume":"12","author":"Kumar","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.34.6.761","article-title":"Respiratory syncytial virus neutralizing antibodies in persons residing in Chicago, Illinois","volume":"34","author":"Beem","year":"1964","journal-title":"Pediatrics"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.137.12.3973","article-title":"Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants","volume":"137","author":"Bangham","year":"1986","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1128\/JVI.02349-15","article-title":"Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach","volume":"90","author":"Aljabr","year":"2016","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin\u2019s antiviral mechanism of action: Lethal mutagenesis?","volume":"80","author":"Crotty","year":"2002","journal-title":"J. Mol. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/CEOR.S60710","article-title":"Respiratory syncytial virus: Current and emerging treatment options","volume":"6","author":"Turner","year":"2014","journal-title":"Clin. Outcomes Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1128\/JVI.02699-09","article-title":"Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion","volume":"84","author":"Huang","year":"2010","journal-title":"J. Virol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"571609","DOI":"10.1155\/2014\/571609","article-title":"Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective","volume":"2014","author":"Homaira","year":"2014","journal-title":"Int. J. Pediatr."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1440-1754.2002.00057.x","article-title":"Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants","volume":"38","author":"Vogel","year":"2002","journal-title":"J. Paediatr. Child. Health"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Mankad, V.S., Leach, A., Chang, Y., W\u00e4hlby Hamr\u00e9n, U., Kiazand, A., Kubiak, R.J., Takas, T., Villafana, T., and Shroff, M. (2024). Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials. Pathogens, 13.","DOI":"10.3390\/pathogens13060503"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Brady, T., Cayatte, C., Roe, T.L., Speer, S.D., Ji, H., Machiesky, L., Zhang, T., Wilkins, D., Tuffy, K.M., and Kelly, E.J. (2023). Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1283120"},{"key":"ref_154","unstructured":"(2026, August 12). Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.46.3.841-847.2002","article-title":"RFI-641, a potent respiratory syncytial virus inhibitor","volume":"46","author":"Huntley","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/v5010211","article-title":"Respiratory syncytial virus entry inhibitors targeting the F protein","volume":"5","author":"Sun","year":"2013","journal-title":"Viruses"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-024-01858-5","article-title":"Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"169084","DOI":"10.1016\/j.jmb.2025.169084","article-title":"The G Protein Inhibitor YM-254890 is an Allosteric Glue","volume":"437","author":"Trent","year":"2025","journal-title":"J. Mol. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02576-20","article-title":"Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Rhodin, M.H.J., McAllister, N.V., Castillo, J., Noton, S.L., Fearns, R., Kim, I.J., Yu, J., Blaisdell, T.P., Panarese, J., and Shook, B.C. (2021). EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009428"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"Chapman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","unstructured":"(2026, August 12). Available online: https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir\/."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijid.2014.03.1394","article-title":"Human metapneumovirus: Review of an important respiratory pathogen","volume":"25","author":"Panda","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-025-02626-5","article-title":"Human metapneumovirus (hMPV): The virus who came with the common cold","volume":"54","author":"Pandey","year":"2026","journal-title":"Infection"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Dong, Y., Xie, Z., and Xu, L. (2025). Receptors and host factors: Key players in human metapneumovirus infection. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1557880"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/JVI.80.6.3071-3077.2006","article-title":"Analysis of the pH requirement for membrane fusion of different isolates of the paramyxovirus parainfluenza virus 5","volume":"80","author":"Bissonnette","year":"2006","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1128\/JVI.01287-06","article-title":"Characterization of human metapneumovirus F protein-promoted membrane fusion: Critical roles for proteolytic processing and low pH","volume":"80","author":"Schowalter","year":"2006","journal-title":"J. Virol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00705-013-1622-x","article-title":"Human metapneumovirus G protein is highly conserved within but not between genetic lineages","volume":"158","author":"Yang","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1099\/vir.0.2008\/006957-0","article-title":"Evolutionary dynamics of human and avian metapneumoviruses","volume":"89","author":"Osterhaus","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"105405","DOI":"10.1016\/j.antiviral.2022.105405","article-title":"Antiviral strategies against human metapneumovirus: Targeting the fusion protein","volume":"207","author":"Bailly","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s42003-023-04990-0","article-title":"Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases","volume":"6","author":"Kleiner","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Huang, J., Diaz, D., and Mousa, J.J. (2020). Antibody recognition of the Pneumovirus fusion protein trimer interface. PLoS Pathog., 16.","DOI":"10.1101\/2020.05.20.107508"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"104364","DOI":"10.1016\/j.drudis.2025.104364","article-title":"An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities","volume":"30","author":"Laufer","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Kishko, M., Stuebler, A., Sasmal, S., Chan, Y., Huang, D., Reyes, C., Lin, J., Price, O., Kume, A., and Zong, K. (2025). A Computationally Designed Prefusion Stabilized Human Metapneumovirus Fusion Protein Vaccine Antigen Elicited a Potent Neutralization Response. Vaccines, 13.","DOI":"10.3390\/vaccines13050523"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e0028425","DOI":"10.1128\/jvi.00284-25","article-title":"Human metapneumovirus: Understanding the molecular mechanisms and pathology of infection","volume":"99","author":"Heim","year":"2025","journal-title":"J. Virol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/JVI.79.11.6588-6597.2005","article-title":"Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: Effects on RNA synthesis, attenuation, and immunogenicity","volume":"79","author":"Buchholz","year":"2005","journal-title":"J. Virol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"G\u00e1lvez, N.M.S., Andrade, C.A., Pacheco, G.A., Soto, J.A., Stranger, V., Rivera, T., V\u00e1squez, A.E., and Kalergis, A.M. (2021). Host Components That Modulate the Disease Caused by hMPV. Viruses, 13.","DOI":"10.3390\/v13030519"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Aerts, L., Cavanagh, M.H., Dubois, J., Carbonneau, J., Rh\u00e9aume, C., Lavigne, S., Couture, C., Hamelin, M., and Boivin, G. (2015). Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120283"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Bao, X., Liu, T., Shan, Y., Li, K., Garofalo, R.P., and Casola, A. (2008). Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000077"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Velayutham, T.S., Ivanciuc, T., Garofalo, R.P., and Casola, A. (2022). Role of human metapneumovirus glycoprotein G in modulation of immune responses. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.962925"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Principi, N., Fainardi, V., and Esposito, S. (2025). Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment. Viruses, 17.","DOI":"10.3390\/v17081140"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"105758","DOI":"10.1016\/j.meegid.2025.105758","article-title":"Emerging threat of Human Metapneumovirus (HMPV) and strategies for its containment and control","volume":"131","author":"Gnanasekaran","year":"2025","journal-title":"Infect. Genet. Evol."},{"key":"ref_184","first-page":"2025.01.13.632889","article-title":"Exploring FDA-approved antiviral drugs for human metapneumovirus treatment: Integrative computational insights","volume":"bioRxiv","author":"Dubey","year":"2025","journal-title":"bioRxiv"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.insi.2025.100097","article-title":"Repurposing FDA-approved asthma drugs against human metapneumovirus: A network pharmacology and molecular simulation approach","volume":"1","author":"Roney","year":"2025","journal-title":"In Silico Res. Biomed."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.coviro.2023.101337","article-title":"Structural basis for respiratory syncytial virus and human metapneumovirus neutralization","volume":"61","author":"Miller","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41586-019-1759-1","article-title":"Structure of the human metapneumovirus polymerase phosphoprotein complex","volume":"577","author":"Pan","year":"2020","journal-title":"Nature"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"108256","DOI":"10.1016\/j.jbc.2025.108256","article-title":"Regulation of respiratory syncytial virus nucleoprotein oligomerization by phosphorylation","volume":"301","author":"Basse","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Anderson, L.J., Jadhao, S.J., Paden, C.R., and Tong, S. (2021). Functional Features of the Respiratory Syncytial Virus G Protein. Viruses, 13.","DOI":"10.3390\/v13071214"},{"key":"ref_190","unstructured":"Elboukari, H., and Ashraf, M. (2026). Parainfluenza Virus. StatPearls, StatPearls Publishing."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/v1010026","article-title":"The complete sequence of a human parainfluenzavirus 4 genome","volume":"1","author":"Yea","year":"2009","journal-title":"Viruses"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.str.2005.02.019","article-title":"Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose","volume":"13","author":"Yuan","year":"2005","journal-title":"Structure"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e00803","DOI":"10.1128\/mBio.00803-13","article-title":"Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo","volume":"4","author":"Xu","year":"2013","journal-title":"mBio"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1128\/jvi.67.11.6463-6468.1993","article-title":"Relative affinity of the human parainfluenza virus type 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity","volume":"67","author":"Moscona","year":"1993","journal-title":"J. Virol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Mizukoshi, F., Kimura, H., Sugimoto, S., Kimura, R., Nagasawa, N., Hayashi, Y., Hashimoto, K., Hosoya, M., Shirato, K., and Ryo, A. (2024). Molecular Evolutionary Analyses of the Fusion Genes in Human Parainfluenza Virus Type 4. Microorganisms, 12.","DOI":"10.3390\/microorganisms12081633"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e0116424","DOI":"10.1128\/spectrum.01164-24","article-title":"Comparison of mutations in human parainfluenza viruses during passage in primary human bronchial\/tracheal epithelial air-liquid interface cultures and cell lines","volume":"12","author":"Sugimoto","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41564-024-01722-w","article-title":"Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies","volume":"9","author":"Suryadevara","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"17903","DOI":"10.1073\/pnas.0608678103","article-title":"Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy","volume":"103","author":"Connolly","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"16672","DOI":"10.1073\/pnas.1213802109","article-title":"Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein","volume":"109","author":"Welch","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/AAC.48.5.1495-1502.2004","article-title":"Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo","volume":"48","author":"Alymova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1055\/s-0036-1584798","article-title":"Parainfluenza Virus Infection","volume":"37","author":"Branche","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Luong, Q.X.T., Hoang, P.T., Ho, P.T., Ayun, R.Q., Lee, T.K., and Lee, S. (2025). Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041481"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/653621","article-title":"A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo","volume":"202","author":"Moscona","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1128\/JVI.00475-09","article-title":"Human parainfluenza virus infection of the airway epithelium: Viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity","volume":"83","author":"Palermo","year":"2009","journal-title":"J. Virol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41579-020-00501-8","article-title":"Structural insights into RNA polymerases of negative-sense RNA viruses","volume":"19","author":"Grimes","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.76.16.8101-8109.2002","article-title":"Role of a highly conserved NH(2)-terminal domain of the human parainfluenza virus type 3 RNA polymerase","volume":"76","author":"Malur","year":"2002","journal-title":"J. Virol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"13495","DOI":"10.1128\/JVI.01965-14","article-title":"Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection","volume":"88","author":"Palmer","year":"2014","journal-title":"J. Virol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Shirai, T., Mizukoshi, F., Kimura, R., Matsuoka, R., Sada, M., Shirato, K., Ishii, H., Ryo, A., and Kimura, H. (2025). Molecular Evolution of the Fusion (F) Genes in Human Parainfluenza Virus Type 2. Microorganisms, 13.","DOI":"10.3390\/microorganisms13020399"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/JVI.01226-10","article-title":"Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping","volume":"85","author":"Nishio","year":"2011","journal-title":"J. Virol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e70632","DOI":"10.1002\/jmv.70632","article-title":"Evolutionary Dynamics of Human Parainfluenza Virus Type 1 Based on the Hemagglutinin-Neuraminidase Gene","volume":"97","author":"Lin","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-017-0685-2","article-title":"The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract","volume":"17","author":"Kowalski","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Plattet, P., Alves, L., Herren, M., and Aguilar, H.C. (2016). Measles Virus Fusion Protein: Structure, Function and Inhibition. Viruses, 8.","DOI":"10.3390\/v8040112"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1038\/s41467-025-58985-y","article-title":"Structure of the measles virus ternary polymerase complex","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e00184-18","DOI":"10.1128\/genomeA.00184-18","article-title":"Complete Genome Sequences of Six Measles Virus Strains","volume":"6","author":"Phan","year":"2018","journal-title":"Genome Announc."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Lin, L.T., and Richardson, C.D. (2016). The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein. Viruses, 8.","DOI":"10.3390\/v8090250"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbrc.2004.02.106","article-title":"Characterization of a region involved in binding of measles virus H protein and its receptor SLAM (CD150)","volume":"316","author":"Hu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1128\/JVI.78.18.9666-9674.2004","article-title":"Mechanism of CD150 (SLAM) down regulation from the host cell surface by measles virus hemagglutinin protein","volume":"78","author":"Welstead","year":"2004","journal-title":"J. Virol."},{"key":"ref_219","unstructured":"Baron, S. (1996). Togaviruses: Rubella Virus. Medical Microbiology, University of Texas Medical Branch at Galveston. [4th ed.]."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/S0140-6736(14)60539-0","article-title":"Rubella","volume":"385","author":"Lambert","year":"2015","journal-title":"Lancet"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"001817","DOI":"10.1099\/jgv.0.001817","article-title":"ICTV Virus Taxonomy Profile: Matonaviridae 2022","volume":"103","author":"Mankertz","year":"2022","journal-title":"J. Gen. Virol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"20105","DOI":"10.1073\/pnas.1316681110","article-title":"Rubella virus capsid protein structure and its role in virus assembly and infection","volume":"110","author":"Willows","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1128\/JVI.72.11.8747-8755.1998","article-title":"Effects of mutations in the rubella virus E1 glycoprotein on E1\u2013E2 interaction and membrane fusion activity","volume":"72","author":"Yang","year":"1998","journal-title":"J. Virol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02349-20","article-title":"Molecular and Structural Insights into the Life Cycle of Rubella Virus","volume":"95","author":"Das","year":"2021","journal-title":"J. Virol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/CMR.13.4.571","article-title":"Rubella virus replication and links to teratogenicity","volume":"13","author":"Lee","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_226","first-page":"1","article-title":"Molecular Virology of Rubella Virus","volume":"Volume 15","author":"Banatvala","year":"2007","journal-title":"Rubella Viruses"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1128\/JVI.01075-10","article-title":"The F gene of the Osaka-2 strain of measles virus derived from a case of subacute sclerosing panencephalitis is a major determinant of neurovirulence","volume":"84","author":"Ayata","year":"2010","journal-title":"J. Virol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"39025","DOI":"10.1038\/srep39025","article-title":"Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000\u20132013","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"e0237323","DOI":"10.1128\/mbio.02373-23","article-title":"A single-point mutation in the rubella virus E1 glycoprotein promotes rescue of recombinant vesicular stomatitis virus","volume":"15","author":"Das","year":"2024","journal-title":"mBio"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"205617","DOI":"10.1155\/2014\/205617","article-title":"Mutations in the H, F, or M Proteins Can Facilitate Resistance of Measles Virus to Neutralizing Human Anti-MV Sera","volume":"2014","author":"Kweder","year":"2014","journal-title":"Adv. Virol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.1038\/s41467-025-64128-0","article-title":"Structural basis of measles virus polymerase inhibition by nonnucleoside inhibitor ERDRP-0519","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"pgad256","DOI":"10.1093\/pnasnexus\/pgad256","article-title":"Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus","volume":"2","author":"Dittmar","year":"2023","journal-title":"PNAS Nexus"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/JVI.80.3.1524-1536.2006","article-title":"Two domains that control prefusion stability and transport competence of the measles virus fusion protein","volume":"80","author":"Doyle","year":"2006","journal-title":"J. Virol."},{"key":"ref_234","first-page":"e88196","article-title":"The 2025 United States Measles Crisis: When Vaccine Hesitancy Meets Reality","volume":"17","author":"Adeoye","year":"2025","journal-title":"Cureus"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"e202500532","DOI":"10.1002\/cmdc.202500532","article-title":"A Short Peptide Inhibitor of Measles Virus Fusion Protein that Exhibits Passive Membrane Permeability","volume":"20","author":"Gao","year":"2025","journal-title":"ChemMedChem"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"D\u00fczg\u00fcne\u015f, N., Fernandez-Fuentes, N., and Konopka, K. (2021). Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design. Pathogens, 10.","DOI":"10.3390\/pathogens10121599"},{"key":"ref_237","unstructured":"(2026, August 12). Available online: https:\/\/www.cdc.gov\/rubella\/hcp\/clinical-overview\/index.html."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.09.019","article-title":"Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency","volume":"147","author":"Perelygina","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0264-410X(00)00371-6","article-title":"Inhibition of rubella virus growth by Fungizone","volume":"19","author":"Umino","year":"2001","journal-title":"Vaccine"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1073\/pnas.1718957115","article-title":"Structures of the prefusion form of measles virus fusion protein in complex with inhibitors","volume":"115","author":"Hashiguchi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coviro.2020.04.002","article-title":"Structural characteristics of measles virus entry","volume":"41","author":"Fukuhara","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_242","first-page":"59","article-title":"Measles virus glycoprotein complex assembly, receptor attachment, and cell entry","volume":"329","author":"Navaratnarajah","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"8296","DOI":"10.1128\/JVI.00108-08","article-title":"Measles virus circumvents the host interferon response by different actions of the C and V proteins","volume":"82","author":"Nakatsu","year":"2008","journal-title":"J. Virol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/138920307779941523","article-title":"Human rhinovirus 3C protease as a potential target for the development of antiviral agents","volume":"8","author":"Wanga","year":"2007","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"e0106021","DOI":"10.1128\/JVI.01060-21","article-title":"Chemical Evolution of Rhinovirus Identifies Capsid-Destabilizing Mutations Driving Low-pH-Independent Genome Uncoating","volume":"96","author":"Murer","year":"2022","journal-title":"J. Virol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.49.2.619-626.2005","article-title":"Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor","volume":"49","author":"Binford","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/JVI.79.1.277-288.2005","article-title":"Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer","volume":"79","author":"Appleby","year":"2005","journal-title":"J. Virol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/JVI.78.7.3663-3674.2004","article-title":"VP1 sequencing of all human rhinovirus serotypes: Insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds","volume":"78","author":"Ledford","year":"2004","journal-title":"J. Virol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s42003-024-07213-2","article-title":"Cryo-EM of human rhinovirus reveals capsid-RNA duplex interactions that provide insights into virus assembly and genome uncoating","volume":"7","author":"Mata","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_251","first-page":"301","article-title":"Rhinovirus RNA Polymerase: Structure, Function, and Inhibitors","volume":"2019","author":"Nirwan","year":"2018","journal-title":"Viral Polym."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.chest.2018.12.012","article-title":"Rhinoviruses and Their Receptors","volume":"155","author":"Basnet","year":"2019","journal-title":"Chest"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Zhang, S., Zong, K., Ruan, J., Liu, X., Zhao, X., Zhang, Y., Hu, C., and Li, X. (2025). Discovery of non-covalent rhinovirus 3Cpro inhibitors by molecular docking, in vitro assays, molecular dynamics simulations and DFT analyses. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1560571"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40348-016-0049-3","article-title":"Mechanism of human rhinovirus infections","volume":"3","author":"Blaas","year":"2016","journal-title":"Mol. Cell Pediatr."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Moreira, E.A., Yamauchi, Y., and Matthias, P. (2021). How Influenza Virus Uses Host Cell Pathways during Uncoating. Cells, 10.","DOI":"10.3390\/cells10071722"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/13543784.10.2.369","article-title":"Pleconaril: A novel antipicornaviral drug","volume":"10","author":"Romero","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_257","unstructured":"(2026, August 12). Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780444537171001529."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/JEP.S255211","article-title":"Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections","volume":"13","author":"Coultas","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1128\/AAC.00905-07","article-title":"In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease","volume":"51","author":"Binford","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/344070a0","article-title":"A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection","volume":"344","author":"Marlin","year":"1990","journal-title":"Nature"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/jvi.67.1.390-397.1993","article-title":"Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion","volume":"67","author":"Greve","year":"1993","journal-title":"J. Virol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fvl-2018-0016","article-title":"Antiviral therapeutic approaches for human rhinovirus infections","volume":"13","author":"Casanova","year":"2018","journal-title":"Future Virol."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Ljubin-Sternak, S., and Me\u0161trovi\u0107, T. (2023). Rhinovirus-A True Respiratory Threat or a Common Inconvenience of Childhood?. Viruses, 15.","DOI":"10.3390\/v15040825"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1093\/ofid\/ofab466.134","article-title":"134. KRP-A218, an Orally Active and Selective PI4KB Inhibitor with Broad-Spectrum Anti-Rhinovirus Activity, Has Potent Therapeutic Antiviral Activity In vivo","volume":"8","author":"Matsui","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1099\/vir.0.80164-0","article-title":"Rhinovirus 3C protease precursors 3CD and 3CD\u2019 localize to the nuclei of infected cells","volume":"85","author":"Amineva","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Real-Hohn, A., and Blaas, D. (2021). Rhinovirus Inhibitors: Including a New Target, the Viral RNA. Viruses, 13.","DOI":"10.3390\/v13091784"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0042-6822(91)91006-3","article-title":"Human rhinovirus mutants resistant to low pH","volume":"183","author":"Skern","year":"1991","journal-title":"Virology"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10787-022-00968-2","article-title":"Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases","volume":"30","author":"Shukla","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/mt.2009.202","article-title":"Adenovirus virion stability and the viral genome: Size matters","volume":"17","author":"Kennedy","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_270","first-page":"195","article-title":"Adenovirus","volume":"343","author":"Jason","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11908-010-0084-5","article-title":"The role of adenovirus in respiratory tract infections","volume":"12","author":"Kunz","year":"2010","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Nesti\u0107, D., Bo\u017einovi\u0107, K., Pehar, I., Wallace, R., Parker, A.L., and Majhen, D. (2021). The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101585"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1128\/JVI.00315-16","article-title":"The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection","volume":"90","author":"Pinkert","year":"2016","journal-title":"J. Virol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1126\/science.286.5444.1579","article-title":"Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR","volume":"286","author":"Bewley","year":"1999","journal-title":"Science"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1074\/jbc.M110.168468","article-title":"The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71","volume":"286","author":"Hussain","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.cell.2024.07.048","article-title":"Viral DNA polymerase structures reveal mechanisms of antiviral drug resistance","volume":"187","author":"Shankar","year":"2024","journal-title":"Cell"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1099\/vir.0.061903-0","article-title":"Roles of conserved residues within the pre-NH2-terminal domain of herpes simplex virus 1 DNA polymerase in replication and latency in mice","volume":"95","author":"Terrell","year":"2014","journal-title":"J. Gen. Virol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1128\/JVI.75.9.4176-4183.2001","article-title":"Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin","volume":"75","author":"Krasnykh","year":"2001","journal-title":"J. Virol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1128\/JCM.43.9.4426-4433.2005","article-title":"Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay","volume":"43","author":"Bauer","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jmb.2009.06.057","article-title":"Structure and uncoating of immature adenovirus","volume":"392","author":"Marabini","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4155\/tde.12.155","article-title":"Development of adenovirus capsid proteins for targeted therapeutic delivery","volume":"4","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.3390\/ph3103343","article-title":"Anti-Viral Drugs for Human Adenoviruses","volume":"3","author":"Waye","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/jac\/dkab259","article-title":"Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: A retrospective multicentre cohort study","volume":"76","author":"Stern","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/AAC.41.8.1846","article-title":"Fanconi syndrome associated with cidofovir therapy","volume":"41","author":"Vittecoq","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ndt\/17.1.148","article-title":"Cidofovir-induced end-stage renal failure","volume":"17","author":"Meier","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Verhees, F., Legemaate, D., Demers, I., Jacobs, R., Haakma, W.E., Rousch, M., Kremer, B., and Speel, E.J. (2019). The Antiviral Agent Cidofovir Induces DNA Damage and Mitotic Catastrophe in HPV-Positive and -Negative Head and Neck Squamous Cell Carcinomas In Vitro. Cancers, 11.","DOI":"10.3390\/cancers11070919"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41392-025-02207-w","article-title":"Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fmb-2019-0288","article-title":"Brincidofovir: Understanding its unique profile and potential role against adenovirus and other viral infections","volume":"15","author":"Whited","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"115601","DOI":"10.1016\/j.ejmech.2023.115601","article-title":"Disulfide-incorporated lipid prodrugs of cidofovir: Synthesis, antiviral activity, and release mechanism","volume":"258","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01002-20","article-title":"The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus","volume":"64","author":"Georgi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.emboj.7600597","article-title":"Adenoviral proteins mimic nutrient\/growth signals to activate the mTOR pathway for viral replication","volume":"24","author":"Klupsch","year":"2005","journal-title":"EMBO J."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Dalidowska, I., Gazi, O., Sulejczak, D., Przybylski, M., and Bieganowski, P. (2021). Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042020"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1128\/jvi.71.1.398-404.1997","article-title":"Adenovirus infection stimulates the Raf\/MAPK signaling pathway and induces interleukin-8 expression","volume":"71","author":"Bruder","year":"1997","journal-title":"J. Virol."},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Liu, M., Jiang, L., Cao, W., Wu, J., and Chen, X. (2022). Identification of Inhibitors and Drug Targets for Human Adenovirus Infections. Viruses, 14.","DOI":"10.3390\/v14050959"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Jeyaraj, G., Rajendran, A.K., Sathishkumar, K., Almutairi, B.O., Vadivelu, A., Chokkakula, S., Tu, Y., and Xie, W. (2025). High-resolution protein modeling through Cryo-EM and AI: Current trends and future perspectives\u2014A review. Front. Mol. Biosci., 12.","DOI":"10.3389\/fmolb.2025.1688455"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3390\/v6093563","article-title":"The adenovirus genome contributes to the structural stability of the virion","volume":"6","author":"Saha","year":"2014","journal-title":"Viruses"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Gallardo, J., P\u00e9rez-Illana, M., Mart\u00edn-Gonz\u00e1lez, N., and San Mart\u00edn, C. (2021). Adenovirus Structure: What Is New?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105240"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"12635","DOI":"10.1128\/JVI.79.20.12635-12642.2005","article-title":"Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: Phylogenetic, taxonomic, and clinical implications","volume":"79","author":"Ebner","year":"2005","journal-title":"J. Virol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_304","doi-asserted-by":"crossref","unstructured":"Saha, B., and Parks, R.J. (2017). Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181012"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/903\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:25:33Z","timestamp":1787977533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":304,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathogens15090903"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15090903","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}